Dr. Joerg Heyer is an accomplished leader in Translational Science, Translational Medicine, and Clinical Research with over two decades of experience in the pharmaceutical industry. As the Head of Translational Science and Medicine, Dr. Heyer has demonstrated exceptional expertise in guiding drug development from preclinical stages through to clinical trials. Dr. Heyer has played a pivotal role in the successful development and strategic management of multiple drug programs, including the oncology drug tivozanib and an infectious disease treatment, CP101. Dr. Heyer’s career is distinguished by his contributions to biomarker strategy and assay development, where he has developed and validated numerous clinical biomarker assays and led innovative strategies for integrating standardized assays into clinical trials. His preclinical research achievements include pioneering chimeric mouse models and devising novel dosing strategies, which have been instrumental in advancing targeted therapies and securing major pharmaceutical partnerships. Dr. Heyer has held senior leadership positions at Dynamicure, Finch Therapeutics, and AVEO Pharmaceuticals, among others, where he has successfully managed multi-million-dollar collaborations and built high-performing teams across international sites.

Dr. Heyer’s academic credentials include a Ph.D. from the University of Wuerzburg and postdoctoral research at the Albert Einstein College of Medicine. Dr. Heyer’s extensive publication record and his role as a sought-after speaker at prestigious international conferences underscore his influential contributions to the field.